Back to results
US 9,957,563 B2Granted
Diagnostic methods
AssigneeIsis Innovation Limited
InventorsEmma Link, Sarah Parish, Rory Collins, Mark Lathrop
Life of this patent
Estimating the term…
Abstract
This invention relates to a method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual has altered susceptibility to statin-induced myopathy.
Claims14
A method comprising the steps of:
- assaying, with a primer comprising a polynucleotide sequence set forth in SEQ ID NO:
- 20, for a presence of a cytosine (C) allele at single nucleotide polymorphism (SNP) rs4149056 in the SLCO1B11 gene in a sample obtained from a patient;
- detecting the presence of a C allele in the sample;
- and
- determining that the patient has an increased risk of statin-induced myopathy based on the presence of the C allele in the sample.
2 more elements
A method for prospectively identifying a patient at risk of statin-induced myopathy, the method comprising the steps of:
- (a) obtaining nucleic acid from a patient who is not taking a statin;
- (b) amplifying at least part of a SLCO1B1 gene in the nucleic acid using primers adapted to amplify single nucleotide polymorphism (SNP) rs4149056 in the SLCO1B1 gene, the primers including a primer comprising a polynucleotide sequence set forth in SEQ ID No. 20;
- (c) identifying two thymines (TT) at SNP rs4149056 in the SLCO1B1 gene;
- and
- (d) determining that the patient is at low risk for developing myopathy when taking a statin, based on the identifying of TT at SNP rs4149056 in the SLCO1B1 gene.
2 more elements
Dependencies are inferred from the claim text.